Jun 10, 2020 / 12:50PM GMT
Ziyi Chen - Goldman Sachs Group Inc., Research Division - Equity Analyst
Good morning, everyone. Thank you for joining the BeiGene session at Goldman Sachs Global Healthcare Conference. This is Ziyi Chen, China Healthcare Analyst. For this session, joining us are John Oyler, Chairman, Co-Founder and CEO of BeiGene; Howard Liang, CFO and Chief Strategy Officer; and Eric Hedrick, Chief Advisor. So thank you all for attending the call.
To start with -- start our session, actually, 2020 marks the 10th-year anniversary for BeiGene. So it has been a tremendous decade for BeiGene growing from a smaller biotech start-up to a well-established pharma company. And particularly, we already bear our footprint in 2 largest pharma markets in China and also U.S.
Questions and Answers:
Ziyi Chen - Goldman Sachs Group Inc., Research Division - Equity AnalystSo what is your expiration (sic) [expectation] for BeiGene in the upcoming decades? How should we think of BeiGene's scale in operation and also global footprint like 10 years from now? John?
Trustpilot
